Long-term natalizumab treatment enhances the pathogenic signature of Th17 cells - potential implications for treatment cessation?
Janoschka C, Schulte-Mecklenbeck A, Starost L, Schafflick D, Schneider-Hohendorf T, Hoerste GM, Gross CC, Schwab N, Kuhlmann T, Wiendl H, Klotz L
Research article (journal) | Peer reviewedDetails about the publication
Journal: Multiple Sclerosis (Mult Scler)
Volume: 24
Issue: 2
Page range: 669-670
Status: Published
Release year: 2018
Language in which the publication is written: English
Authors from the University of Münster
| Groß, Catharina | Department for Neurology |
| Janoschka, Claudia | Department for Neurology |
| Klotz, Luisa Hildegard | Department for Neurology |
| Meyer zu Hörste, Gerd | Department for Neurology |
| Schafflick, David | Department for Neurology |
| Schneider-Hohendorf, Tilman | Department for Neurology |
| Schulte-Mecklenbeck, Andreas | Department for Neurology |
| Wiendl, Heinz Siegfried | Department for Neurology |